Researchers identify a treatment for a rare bone loss disorder that might also lead to help for aging brittle bones
A possible ‘first-line’ treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Hajdu-Cheney syndrome is a rare genetic disease that leads to severe osteoporosis and developmental defects, including the reabsorption of bones in the hands and feet. The disease is associated with mutations in a particular gene, called NOTCH2, which codes for proteins involved with bone maintenance. The NOTCH2 proteins usually help balance destruction and construction essential for bone maintenance and repair. Mutations associated with Hajdu-Cheney syndrome upset that balance, but the exact mechanisms causing bone resorption have not been well understood.
Now, through a series of detailed tests, molecular biologist Hiroyuki Inuzuka and his colleagues have worked out the specific molecular pathway that results in Hajdu-Cheney syndrome.
They found that this particular NOTCH2 mutation does not maintain normal NOTCH2 protein abundance, with the help of another protein, called FBW7. To discover this, the researchers knocked out the gene for Fbw7 in the bones of mice. Without the gene and resulting protein, the mice had severe osteoporosis, much like people with Hajdu-Cheney syndrome — indicating that FBW7 is the primary regulator of this system.
They further determined that in humans with Hajdu-Cheney syndrome, the FBW7 protein was unable to bind to NOTCH2 proteins because the binding spot is missing in osteoclasts. This mutation allows the osteoclasts to over-operate, breaking down too much bone tissue.
The researchers were able to reverse bone loss in the knock-out mice with the elevated NOTCH2 by giving them a medication that blocks osteoclast formation. They tried several different treatments, including a chemical compound called DAPT that was particularly effective. DAPT has been shown to help with osteoarthritis by inhibiting function of NOTCH proteins in other studies. Using DAPT as well as Zoledronic acid, a common medication for osteoporosis, “may become a first-line treatment for Hadju-Cheney syndrome,” the researchers conclude in their study.
“By clearly identifying the relationship between FBW7 and NOTCH2 proteins, we have identified potential therapeutic targets for patients with rare bone diseases as well as much more widespread age-related osteoporosis,” said Inuzuka.
Learn more: Reversing severe bone loss
The Latest on: Bone loss
via Google News
The Latest on: Bone loss
- Scientists get new molecular insights on bone loss: report on April 16, 2019 at 11:22 pm
BEIJING: Scientists for the first time have clearly seen the molecular structure where a hormone related to osteoporosis attaches to the body, providing valuable insight into potential therapies ... […]
- Amgen prices bone drug Evenity on par with rival Tymlos, but a tough marketing road lies ahead on April 16, 2019 at 9:18 am
can prevent bone loss but don’t stimulate bone growth. Last Tuesday, the FDA approved Evenity to treat osteoporosis in post-menopausal women at high risk of fracture. But the approval comes with a ... […]
- Scientists get new molecular insights on bone loss on April 15, 2019 at 5:31 pm
Scientists for the first time have clearly seen the molecular structure where a hormone related to osteoporosis attaches to the body, providing valuable insight into potential therapies. World Health ... […]
- Oral Contraceptives Offer Some Protection Against Bone Loss in Anorexia Nervosa on April 12, 2019 at 5:00 am
Participants with more forms of severe anorexia nervosa showed the best bone tissue responses to oral contraceptives. For young women with anorexia nervosa (AN), oral contraceptives may limit bone ... […]
- Bone health deserves attention on April 11, 2019 at 11:09 am
By making wise eating and lifestyle choices, we can slow the natural process of bone loss and reduce your risk of osteoporosis. For more information on bone health, contact your local health ... […]
- Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug on April 10, 2019 at 7:56 pm
... with a unique dual effect of increasing bone formation and to a lesser extent reducing bone loss, thereby rapidly reducing the risk of fracture. One dose of Evenity consists of two injections ... […]
- Blood flow restriction therapy may minimize muscle, bone loss after ACL reconstruction on April 10, 2019 at 6:14 am
LAS VEGAS — Blood flow restriction therapy may minimize the loss and enhance the recovery of muscle during ACL rehabilitation, according to results presented here. “[Blood flow restriction] BFR also ... […]
- Dietary Calcium Intake Unrelated to Postmenopausal Bone Loss in Women With Osteopenia on April 4, 2019 at 5:00 am
There was no relationship between change in BMD and quintile of calcium intake at any site over the course of 6 years. There is no association between dietary calcium intake and postmenopausal bone ... […]
- Restricting Blood Flow May Prevent ACL Surgery Bone Loss on March 27, 2019 at 10:01 am
A new study suggests that combining blood flow restriction (BFR) therapy with traditional rehabilitation may slow bone loss following anterior cruciate ligament (ACL) reconstruction surgery. ... […]
via Bing News